Text Size




Home | Clinical Trials

FDA Approved Drugs » 1998
Medical Areas: Neurology | Family Medicine

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Excedrin Migraine

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Bristol-Myers Squibb
Approval Status: Approved January 1998
Treatment Area: Mild-to-moderate migraine

General Information

Bristol-Myers Squibb received approval of its Excedrin Migraine for the treatment of pain associated with mild-to-moderate migraine. It is the first over the counter drug to be approved for this indication.

Clinical Results

In trials involving about 1300 migraineurs, Excedrin Migraine was found safe and effective in relieving migraine pain within 2-to-4 hours of dosing.

Mechanism of Action

Excedrin Migraine contains 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine in each tablet. The ingredients are the same as those in Excedrin Extra, which is already on the market, but the product comes with instructions and warnings specific to migraine.

 Back to Top | Printer Friendly Version

Get Involved

Stroke and You

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

National Stroke Association

9707 E. Easter Lane, Suite B
Centennial, CO 80112